Videos

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

Explore the latest FDA-approved treatments for hemophilia, including fitusiran and new anti-tissue factor inhibitors, enhancing patient care.

In this episode, the panel discusses key considerations for selecting and dosing VMAT2 inhibitors in tardive dyskinesia.

In this episode, the panel reviews the efficacy and safety data supporting deutetrabenazine and valbenazine for tardive dyskinesia.

Explore how pharmacists enhance access to care for multiple sclerosis patients, tackling barriers in diagnosis, treatment, and patient education.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.

Pharmacists play a crucial role in educating patients with multiple sclerosis about treatment options, adverse effects, and navigating insurance challenges.

Experts discuss the need for improved clinical trials in myelofibrosis, focusing on disease modification, patient outcomes, and potential new therapies.

Explore the evolving role of pharmacists in managing EGFR-mutated non-small cell lung cancer and the future of resistance-directed therapies.

Reducing alcohol intake alongside GLP-1 therapy may significantly improve outcomes for patients with obesity or diabetes risk.

Ben Long, MD, and Weston Blakeslee, PhD, discuss how pharmacists can integrate automated SMS tools to reduce readmissions while minimizing workflow burden.

Explore how pneumococcal vaccine efficacy is measured, its real-world impact, and the importance of immunobridging for informed vaccination decisions.

On Chen, MD, and Tahmid Rahman, MD, explain the real-world safety, dosing advantages, and pharmacist-driven identification strategies for patients who may benefit from plozasiran therapy.

In this episode, the panel explains how VMAT2 inhibitors became the foundation of modern tardive dyskinesia treatment.

Healthcare professionals discuss effective management strategies for breakthrough bleeding, emphasizing updated protocols and patient education for optimal outcomes.

This episode outlines all treatment approaches available for tardive dyskinesia and how they are applied in practice.

Explore the evolving landscape of bleeding management with new rebalancing agents, emphasizing lower doses and effective treatment strategies.

Plozasiran offers a novel RNA-based mechanism to significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome.

Ben Long, MD; and Weston Blakeslee, PhD, explain how personalized text messaging helps overcome common adherence barriers and keeps patients engaged without overwhelming them.

Heidi De Souza discusses strategies to enhance RSV vaccine uptake among older adults, emphasizing awareness, coadministration patterns, and public health efforts.

Discover how ENAMEL revolutionizes oral care with eco-friendly, waterless toothpaste tablets made from clean, natural ingredients.

Explore how real-world evidence shapes myelofibrosis treatment, focusing on biomarker utilization and safety profiles of JAK inhibitors.

Subcutaneous Amivantamab shows promise with reduced infusion reactions and improved patient convenience, potentially transforming treatment experiences.

Pharmacists play a crucial role in implementing novel therapies for non-small cell lung cancer, focusing on education, communication, and patient safety.

Explore the latest advancements in myelofibrosis treatments, including Fedratinib, Pacritinib, and Momelotinib, and their clinical impacts.

Ben Long, MD; and Weston Blakeslee, PhD, discuss how personalized text reminders significantly improve prescription adherence in patients with heart failure and the critical role pharmacists play in reinforcing engagement.

Jeffery A. Goad, PharmD, MPH, stresses that consistent, evidence-based communication from pharmacists and other health care professionals is essential to maintaining public trust and preventing declines in childhood vaccination.

Zahra Mahmoudjafari explains how the epcoritamab, rituximab, and lenalidomide regimen delivers durable responses in relapsed or refractory follicular lymphoma while expanding the pharmacist’s role in dosing coordination and toxicity management.